“Cardiovascular medication education should be clinically accurate, appropriately cautious, and clear enough for patients making real decisions about access and cost.”
Canadian interventional cardiology, applied to anticoagulant patient education
Dr. Aun-Yeong Chong is a staff interventional cardiologist at the University of Ottawa Heart Institute and Assistant Professor of Medicine at the University of Ottawa. His clinical practice centers on percutaneous coronary intervention, chronic total occlusion PCI, intravascular imaging, invasive assessment of coronary physiology, and transradial procedures.
He studied medicine at the University of New South Wales in Sydney, gained MRCP(UK) through the Royal College of Physicians in 2001, and conducted research at the Haemostasis, Thrombosis and Vascular Biology Unit at City Hospital, Birmingham. He earned his Doctorate in Medicine from the University of Birmingham in 2006 for a thesis on endothelial function in congestive heart failure, completed cardiology training in the West Midlands, and finished an interventional cardiology fellowship at the University of Ottawa Heart Institute in 2008–09 before joining the Institute as staff cardiologist in 2013.
For SunnyPharma, Dr. Chong provides independent clinical review of cardiovascular and anticoagulant education only — content covering rivaroxaban (Xarelto), apixaban (Eliquis) and other direct oral anticoagulants, atrial fibrillation, venous thromboembolism, coronary artery disease, and bleeding-risk and medication-access considerations. His remit is to confirm that patient-facing material is accurate, balanced, appropriately caveated, and useful to people weighing treatment access and cost. SunnyPharma is an independent health-education platform; Dr. Chong does not review content outside cardiovascular and anticoagulant therapy.
My research and clinical work sit at the intersection of thrombosis, coronary physiology, and vascular biology — the same evidence base that underpins how anticoagulant medicines are used and explained.
Field of specialization
Dr. Chong’s clinical and academic work spans interventional cardiology, coronary physiology, thrombosis biology, and cardiovascular medication safety. The areas most relevant to his SunnyPharma review work include:
Published cardiovascular & thrombosis-related work
Dr. Chong’s peer-reviewed record includes work on endothelial dysfunction, thrombotic risk in heart failure, atrial fibrillation biomarkers, anticoagulation after PCI, and antiplatelet therapy. Selected publications relevant to SunnyPharma’s cardiovascular and anticoagulant review work:
- Prophylactic warfarin therapy after primary PCI for anterior ST-segment elevation myocardial infarction
- Ticagrelor for the treatment of peripheral arterial disease
- Influence of atrial fibrillation on plasma von Willebrand factor, soluble E-selectin and NT-proBNP in systolic heart failure
- Plasma angiopoietin-1, angiopoietin-2 and angiopoietin receptor Tie-2 levels in congestive heart failure
- Endothelial activation, dysfunction and damage in congestive heart failure
Full publication record: PubMed author search ↗ · University of Ottawa Heart Institute profile ↗
Review standards & editorial transparency
Content reviewed by Dr. Chong is evaluated for clinical accuracy, patient-safety framing, appropriate anticoagulant cautions, and a clear distinction between drug information, access information, and medical advice. For rivaroxaban, apixaban and related content, review priorities include indication-appropriate language, bleeding-risk cautions, renal-function caveats, drug-interaction context, adherence warnings, and the consistent reminder that patients should consult their own licensed clinician before starting, stopping, or switching therapy.